These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

465 related articles for article (PubMed ID: 25897893)

  • 21. Dephosphorylation of Plk1 occurs through PP2A-B55/ENSA/Greatwall pathway during mitotic DNA damage recovery.
    Kim SY; Hyun SY; Jang YJ
    Cell Cycle; 2019 May; 18(10):1154-1167. PubMed ID: 31072185
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The effect of a PP2A inhibitor on the nuclear receptor corepressor pathway in glioma.
    Lu J; Zhuang Z; Song DK; Mehta GU; Ikejiri B; Mushlin H; Park DM; Lonser RR
    J Neurosurg; 2010 Aug; 113(2):225-33. PubMed ID: 20001590
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The effect of protein phosphatase 2A inhibitor LB100 on regulating methamphetamine induced conditioned place preference in mice.
    Qian H; Wang J; Shang Q; Xiao J; Chen G; Gao B; Liang M; Li T; Liu X
    Neurosci Lett; 2020 Mar; 721():134817. PubMed ID: 32032748
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inhibition of serine/threonine phosphatase PP2A enhances cancer chemotherapy by blocking DNA damage induced defense mechanisms.
    Lu J; Kovach JS; Johnson F; Chiang J; Hodes R; Lonser R; Zhuang Z
    Proc Natl Acad Sci U S A; 2009 Jul; 106(28):11697-702. PubMed ID: 19564615
    [TBL] [Abstract][Full Text] [Related]  

  • 25. PP2A and tumor radiotherapy.
    Lei X; Ma N; Du L; Liang Y; Zhang P; Han Y; Qu B
    Hereditas; 2020 Aug; 157(1):36. PubMed ID: 32847617
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Protein phosphatase 2A as a potential target for anticancer therapy.
    Kalev P; Sablina AA
    Anticancer Agents Med Chem; 2011 Jan; 11(1):38-46. PubMed ID: 21288198
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Erlotinib derivative inhibits hepatocellular carcinoma by targeting CIP2A to reactivate protein phosphatase 2A.
    Yu HC; Hung MH; Chen YL; Chu PY; Wang CY; Chao TT; Liu CY; Shiau CW; Chen KF
    Cell Death Dis; 2014 Jul; 5(7):e1359. PubMed ID: 25077545
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cancerous inhibitor of protein phosphatase 2A, an emerging human oncoprotein and a potential cancer therapy target.
    Khanna A; Pimanda JE; Westermarck J
    Cancer Res; 2013 Nov; 73(22):6548-53. PubMed ID: 24204027
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Enhanced anticancer activity of a protein phosphatase 2A inhibitor on chemotherapy and radiation in head and neck squamous cell carcinoma.
    Zhu DW; Yuan YX; Qiao JK; Yu C; Yang X; Wang LZ; Zhang ZY; Zhong LP
    Cancer Lett; 2015 Jan; 356(2 Pt B):773-80. PubMed ID: 25449438
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Review of PP2A Tumor Biology and Antitumor Effects of PP2A Inhibitor LB100 in the Nervous System.
    Bryant JP; Levy A; Heiss J; Banasavadi-Siddegowda YK
    Cancers (Basel); 2021 Jun; 13(12):. PubMed ID: 34205611
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The substrate of Greatwall kinase, Arpp19, controls mitosis by inhibiting protein phosphatase 2A.
    Gharbi-Ayachi A; Labbé JC; Burgess A; Vigneron S; Strub JM; Brioudes E; Van-Dorsselaer A; Castro A; Lorca T
    Science; 2010 Dec; 330(6011):1673-7. PubMed ID: 21164014
    [TBL] [Abstract][Full Text] [Related]  

  • 32. RABL6A inhibits tumor-suppressive PP2A/AKT signaling to drive pancreatic neuroendocrine tumor growth.
    Umesalma S; Kaemmer CA; Kohlmeyer JL; Letney B; Schab AM; Reilly JA; Sheehy RM; Hagen J; Tiwari N; Zhan F; Leidinger MR; O'Dorisio TM; Dillon J; Merrill RA; Meyerholz DK; Perl AL; Brown BJ; Braun TA; Scott AT; Ginader T; Taghiyev AF; Zamba GK; Howe JR; Strack S; Bellizzi AM; Narla G; Darbro BW; Quelle FW; Quelle DE
    J Clin Invest; 2019 Mar; 129(4):1641-1653. PubMed ID: 30721156
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The concept of the okadaic acid class of tumor promoters is revived in endogenous protein inhibitors of protein phosphatase 2A, SET and CIP2A, in human cancers.
    Fujiki H; Sueoka E; Watanabe T; Suganuma M
    J Cancer Res Clin Oncol; 2018 Dec; 144(12):2339-2349. PubMed ID: 30341686
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Chk1 targeting reactivates PP2A tumor suppressor activity in cancer cells.
    Khanna A; Kauko O; Böckelman C; Laine A; Schreck I; Partanen JI; Szwajda A; Bormann S; Bilgen T; Helenius M; Pokharel YR; Pimanda J; Russel MR; Haglund C; Cole KA; Klefström J; Aittokallio T; Weiss C; Ristimäki A; Visakorpi T; Westermarck J
    Cancer Res; 2013 Nov; 73(22):6757-69. PubMed ID: 24072747
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Protein phosphatase 2A as a potential target for treatment of adult T cell leukemia.
    Mori N; Ishikawa C; Uchihara JN; Yasumoto T
    Curr Cancer Drug Targets; 2013 Oct; 13(8):829-42. PubMed ID: 24015987
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Antitumor Drug LB-100 Is a Catalytic Inhibitor of Protein Phosphatase 2A (PPP2CA) and 5 (PPP5C) Coordinating with the Active-Site Catalytic Metals in PPP5C.
    D'Arcy BM; Swingle MR; Papke CM; Abney KA; Bouska ES; Prakash A; Honkanen RE
    Mol Cancer Ther; 2019 Mar; 18(3):556-566. PubMed ID: 30679389
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Interaction mechanism of endogenous PP2A inhibitor protein ENSA with PP2A.
    Thapa C; Roivas P; Haataja T; Permi P; Pentikäinen U
    FEBS J; 2022 Jan; 289(2):519-534. PubMed ID: 34346186
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacologic inhibition of protein phosphatase-2A achieves durable immune-mediated antitumor activity when combined with PD-1 blockade.
    Ho WS; Wang H; Maggio D; Kovach JS; Zhang Q; Song Q; Marincola FM; Heiss JD; Gilbert MR; Lu R; Zhuang Z
    Nat Commun; 2018 May; 9(1):2126. PubMed ID: 29844427
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Inhibiting protein phosphatase 2A increases the antitumor effect of protein arginine methyltransferase 5 inhibition in models of glioblastoma.
    Otani Y; Sur HP; Rachaiah G; Namagiri S; Chowdhury A; Lewis CT; Shimizu T; Gangaplara A; Wang X; Vézina A; Maric D; Jackson S; Yan Y; Zhengping Z; Ray-Chaudhury A; Kumar S; Ballester LY; Chittiboina P; Yoo JY; Heiss J; Kaur B; Banasavadi-Siddegowda YK
    Neuro Oncol; 2021 Sep; 23(9):1481-1493. PubMed ID: 33556161
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Palbociclib enhances radiosensitivity of hepatocellular carcinoma and cholangiocarcinoma via inhibiting ataxia telangiectasia-mutated kinase-mediated DNA damage response.
    Huang CY; Hsieh FS; Wang CY; Chen LJ; Chang SS; Tsai MH; Hung MH; Kuo CW; Shih CT; Chao TI; Chen KF
    Eur J Cancer; 2018 Oct; 102():10-22. PubMed ID: 30103095
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.